Reported Earlier, MediciNova Receives U.S. Patent Allowance For MN-166, Ensuring Broad Protection For Post-COVID Treatment Through 2042
Reported Earlier, MediciNova Receives U.S. Patent Allowance For MN-166, Ensuring Broad Protection For Post-COVID Treatment Through 2042
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), announces that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application, which covers MN-166 (ibudilast) for post-COVID conditions. The Method of Use patent covers administering a therapeutically effective doses of ibudilast (or a pharmaceutically acceptable salt thereof) to alleviate a range of post-COVID conditions including anxiety, fatigue, depression, shortness of breath, post-traumatic stress disorder, chest tightness, palpitations, smell or taste dysfunction, sleep difficulties, hair loss, and rash.
位于纳斯达克全球市场（NASDAQ:MNOV）和东京证券交易所标准市场（代码：4875）上市的生物制药公司MediciNova, Inc.宣布，其一项待审专利申请已经获得美国专利和商标局的批准通知，该专利涵盖了ibudilast（即MN-166）用于新冠后症状的方法。该使用方法专利涵盖了以治疗有效剂量的ibudilast（或其药学可接受的盐）来缓解一系列新冠后症状，包括焦虑、疲劳、抑郁、呼吸困难、创伤后压力障碍、胸闷、心悸、嗅觉或味觉障碍、睡眠困难、脱发和皮疹。
